a:5:{s:8:"template";s:9437:" {{ keyword }}

{{ text }}
{{ links }} ";s:4:"text";s:28274:"References •This lecture •Hand-outs. Exosomes were isolated via ultracentrifugation after serum samples were collected. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. With effective treatment within our grasp, accurate and rapid diagnosis is of major medical and economic importance. Myocardial remodeling is the pivotal process leading to progressive myocardial dysfunction and risk in HF. Early detection of acute myocardial infarction is crucial for deciding the course of treatment to preserve and prevent further damage to the myocardial tissue. Part of the evaluation includes analysis of serum cardiac markers or enzymes. Methods Myocardial infarction causes significant mortality and morbidity. doi: 10.1016/j.cca.2006.02.042. They can be useful in the early prediction or diagnosis of disease. The incidence of acute myocardial infarction (AMI) has been increasing rapidly in recent years, seriously endangering human health. Acute myocardial infarction (AMI) is the common cause of mortality in developed countries. CiteSeerX - Document Details (Isaac Councill, Lee Giles, Pradeep Teregowda): Myocardial infarction causes significant mortality and morbidity. 2. Non-ST segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI) are both commonly known as heart attack. We aimed to identify monocyte-related critical genes as predictive biomarkers for post-AMI HF. ACS carries significant morbidity and mortality and the prompt diagnosis, and appropriate treatment is essential. Timing is important, as are correlation with patient symptoms, electrocardiograms, and angiographic studies. While BNP, NT-proBNP and hsTn are all also linked to remodeling risk, other biomarkers are worth mention. Myocardial infarction is defined as myocardial necrosis in a clinical setting consistent with myocardial ischemia . The rupture of a coronary atherosclerotic plaque can block or dramatically restrict the blood flow to the myocardium, causing … A total of 230 volunteers were recruited, consisting of 146 chest pain patients … BACKGROUND: The observed incidence of type 2 myocardial infarction (T2MI) is expected to increase with the implementation of increasingly sensitive cTn assays. Acute Myocardial Infarction •A rapid development of myocardial necrosis caused by prolonged ischemia (a critical imbalance between the oxygen supply and demand of the Myocardial Remodeling. PURPOSE: The effects of physical activity on risk of myocardial infarction (MI) are well documented and may include beneficial changes in blood lipids, inflammatory markers, and insulin sensitivity. the clinical value of the identied biomarkers is still limited. Acute myocardial infarction (AMI) is a major contributor of heart failure (HF). Public Diagram. To assess serial changes in cDTI biomarkers in participants following ST-segment elevation myocardial infarction (STEMI) and to determine their associations with long-term left ventricular remodeling. Myocardial Infarction (MI), Cardiac Biomarkers Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. death of myocardial tissue secondary to prolonged and severe ischemia . Cardiac biomarkers/enzymes: The American College of Cardiology/American Heart Association (ACC/AHA) guidelines on unstable angina/NSTEMI (non–ST-segment elevation myocardial infarction) recommend that in patients with suspected myocardial infarction, cardiac biomarkers should be measured at presentation Top 5 biomarkers of a myocardial infarction and other heart ailments New research has discovered an AI-based method to predict the future risk of a myocardial infarction … 2006;369(2):179–187. Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction or acute coronary syndrome. However, many clinicians are unaware that MI itself is classified into five types, the most common being type I, followed by type II. December 20, 2010 by Greg 16 Comments. If you continue browsing the site, you agree to the use of cookies on this website. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Background Elevated levels of osteoprotegerin (OPG) have been associated with adverse outcomes in ST-elevation myocardial infarction (STEMI). Question Can novel cardiovascular biomarkers aid physicians in the early discrimination of type 2 myocardial infarction (T2MI) from type 1 myocardial infarction (T1MI)? Page 2 of 8. of multiple biomarkers and the use of point of care markers may accelerate current diagnostic protocols for the assessment of such patients. Universal definition of myocardial infarction has been under the joint auspices of the European Society of Cardiology, American College of Cardiology Foundation, American Heart Association and World Heart Federation [1]. The history, ECG and cardiac biomarkers depend upon the early diagnosis of acute myocardial infarction (AMI). Materials and Methods. A few novel biomarkers mentioned in this article showed significant relation to left ventricle remodelling and poor prognosis after myocardial infarction. The morbidity and mortality associated with acute myocardial infarction are well understood and discussed elsewhere. Acute myocardial infarction (AMI) is defined by the presence of myocardial necrosis in the clinical setting of acute myocardial ischemia as supported by history, physical examination, electrocardiograph (ECG) findings, and biochemical markers of myocardial necrosis. myocardial infarction, and invasive investigation and revascularisation for non-ST-elevation myocardial infarction, ... and biomarkers for early diagnosis and risk stratiﬁ cation.7–9 Many clinical trials have also explored therapeutic innovations, and there is an emerging Myocardial infarction causes significant mortality and morbidity. This study aimed to determine the … We designed a case–control, two-stage, epigenome-wide … However, the role of OPG in myocardial injury and adverse remodeling in STEMI patients remains unclear. [] According to American Heart Association estimates, every 40 seconds an American will have an MI. STEMI is defined by symptoms of myocardial ischemia accompanied by a persistent elevation of the ST segment on the electrocardiogram (ECG) and the subsequent release of biomarkers of myocardial … In addition to electrocardiogram, echocardiography, coronary angiography, etc., circulating biomarkers are essential for the diagnosis, prognosis, and treatment effect monitoring of MI patients. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. A myocardial infarction, according to current consensus, is defined by elevated cardiac biomarkers with a rising or falling trend and at least one of the following: Symptoms relating to ischemia Changes on an electrocardiogram (ECG), such as ST segment changes, new left bundle branch block , … However, these biomarkers exhibit elevated … Myocardial infarction has been classified into types 1 to 5 of which type 4 has subtypes a and b. Background: Acute myocardial infarction (AMI) is an acute disease with high mortality and seriously threatens human health. Since clinical history and physical examination alone are of limited use,1 and a 12-lead ECG is used in a minority of cases, cardiac biomarkers are the cornerstone for the diagnosis of myocardial infarction with non-ST-segment elevation. We aimed to discriminate and risk-stratify T2MI using biomarkers. Cardiac biomarkers are used in conjunction with symptoms, electrocardiographic (ECG) changes, and cardiac imaging to diagnosis acute myocardial infarction (AMI) in patients with chronic kidney disease (CKD) . The feasibility of whole-genome gene expression analysis to identify outcome-related genes and dysregulated pathways remains unknown. Each year, a large number of patients are seen in the Emergency Department with presentations necessitating investigation for possible acute myocardial infarction. ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION). What pattern of elevation is most likely to indicate an acute myocardial infarction? Cardiac Biomarkers in Acute Coronary Syndrome. Although they are often discussed in the context of myocardial infarction, other conditions can lead to an elevation in cardiac marker level. Acute Myocardial Infarction A rapid development of myocardial necrosis caused by prolonged ischemia (a critical imbalance between the oxygen supply and demand of the Cardiac markers are biomarkers measured to evaluate heart function. 1). Biomarkers of myocardial infarction What is myocardial infarction? The diagnosis of acute myocardial infarction (AMI) involves multiple clinical tools including physical assessment, ECG, and the evaluation of cardiac biomarkers. Acute myocardial infarction (AMI) is a common disease with serious consequences in mortality and cost. Serum biomarkers have been used to assist in the diagnosis of acute myocardial infarction for over half a century with aspartate transaminases in the 1950s and lactate dehydrogenase in the 1970s . Ladenson JH. A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). A personal history of markers of myocyte injury [myocardial infarction]. Background Acute myocardial infarction (AMI) is considered one of the most prominent causes of death from cardiovascular disease worldwide. The feasibility of whole-genome gene expression analysis to identify outcome-related genes and dysregulated pathways remains unknown. Type 4a: Myocardial Infarction related to percutaneous coronary intervention (PCI) Type 4b: Myocardial Infarction secondary to stent/scaffold THROMBOSIS myocardial infarction (AMI). ST2. Abstract Myocardial infarction causes significant mortality and morbidity. The nurse is caring for a patient who may have had an acute myocardial infarction. (However the association between biomarkers of inflammation and these imaging parameters is not known). NSTEMI is the less common of the two, accounting for around 30 percent of all heart attacks. ST2 gene is strongly induced in the setting of cardiomyocyte or cardiac fibroblasts stretch. 1 About 10% of patients who are admitted to emergency departments with chest pain every year are diagnosed with heart attack. Cardiac biomarkers – the old and the new: a review. Type 2: Myocardial Infarction secondary to oxygen supply-demand mismatch. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Results: Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4471), type 2 myocardial infarction by 22% (205/916), and acute and chronic myocardial … The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2014 Resources: •This lecture •Hand-outs. Myocardial infarction is the major cause of death worldwide. Proteomic profiling of extracellular vesicles reveals additional diagnostic biomarkers for myocardial infarction compared to plasma alone Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Myocardial infarction is the major cause of death worldwide. We aimed to discriminate and risk-stratify T2MI using biomarkers. Although the incidence of myocardial infarction (MI) has a decreased trend between 1997 and 2008 in the United State, approximate 155,000 new asymptomatic silent cases occur annually, and in developing countries, AMI is still a significant health burden. Patients with cardiogenic shock were excluded. The epigenetic landscape underlying cardiovascular disease (CVD) is not completely understood and the clinical value of the identified biomarkers is still limited. Biomarkers quantifying endothelial dysfunction, microvascular dysfunction, and/or hemodynamic stress provided modest diagnostic performance in the early discrimination of type 2 myocardial infarction (T2MI) from type 1 myocardial infarction (T1MI). [] The estimated incidence is 605,000 new and 200,000 recurrent MIs annually. However, few reports have focused on the value of exosomal miRNAs in the mechanism of the pathophysiological process from stable coronary artery disease (SCAD) to AMI. Methods and Results: We conducted a case-control, two-stage, epigenome-wide association study on acute myocardial infarction (ndiscovery=391, nvalidation=204). Cardiac biomarkers are also used to predict short- and long-term adverse outcomes. The older biomarkers like aspartate transaminase, Citation: Ahmad MI, Sharma N (2012) Biomarkers in Acute Myocardial Infarction. Biochemical markers play a pivotal role in the diagnosis and management of patients with acute myocardial infarction. Myocardial infarction is the major cause of death worldwide. Nanomedicine: Nanotechnology, Biology and … Proteomic profiling of extracellular vesicles reveals additional diagnostic biomarkers for myocardial infarction compared to plasma alone Abstract: Myocardial infarction (MI) causes significant mortality and morbidity. The more sensitive the assay, the more important it is to determine a change for confirmation. To investigate the relationship between trans fatty acids and postmenopausal breast cancer in European populations differing greatly in their dietary fat intakes, a case control study using adipose tissue stores of trans fatty acids as a biomarker of exposure was conducted. Acute myocardial infarction (AMI) was considered to be one of the major causes of morbidity and mortality worldwide. The powerful biomarkers for early identification of AMI patients at risk of HF remain elusive. Whether they provide prognostic information in STEMI, complementary to troponins, has not been fully elucidated. High sensitive and multiple detection of acute myocardial infarction biomarkers based on a dual-readout immunochromatography test strip. Table S3 summarizes the diagnostic and prognostic value of C-reactive protein and copeptin in patients with acute myocardial infarction. Molecular marker such as BNP, CRP and other serum inflammatory markers have got the notice at this point. Myocardial infarction is the major cause of death worldwide. The development of new, high-technology laboratory methods continues to improve therapy monitoring, as well as diagnostic and prognostic accuracy in cardiovascular medicine [36,82]. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. A Glimpse into the Future—Emerging Molecular Candidate Biomarkers for Acute Myocardial Infarction. However, these biomarkers exhibit elevated … In order to manage the acute myocardial infarction outbreaks, accurate biomarkers for risk prediction are needed. Molecular marker such as BNP, CRP and other serum inflammatory markers have got the notice at this point. tion myocardial infarction (STEMI), as the most common and severe type of acute myocardial infarction (AMI), is the major contributor of HF [6]. Methods Patients given opioid treatment by emergency medical services with confirmed STEMI were included in this secondary, retrospective cohort analysis of the Air versus Oxygen in Myocardial Infarction (AVOID) study. We performed a Medline search of articles published in the years 2005–2020 using the keywords: “myocardial infarction AND ventricular remodeling AND biomarkers”. Myocardial infarction causes significant mortality and morbidity. Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction 2020 Jan 17;2020:2018035. doi: 10.1155/2020/2018035. We sought to analyse plasma levels of peripheral blood microRNAs (miRs) as biomarkers of ST-segment-elevation myocardial infarction (STEMI) due to type-1 myocardial infarction … Type 3: Myocardial Infarction resulting in death with unavailable biomarkers. Cardiac biomarkers play critical roles in the diagnosis and prognosis of AMI. Electrocardiography produces a physiological signal that is frequently used for diagnosing heart problems, but it is incapable of adequately diagnosing AMI 8. (Supplementary Materials) Preclinical studies in cardiovascular research are necessary for the translation of basic research to the clinic. 1 Introduction. Cardiac Biomarkers and Acute Myocardial Infarction Troponin Beyond. Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2013. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Cardiac troponin (I or T) is the most reliable biomarker for all types of MI because it has high myocardial … Peripheral blood mononuclear cells (PBMCs), mainly monocytes, are the essential initiators of AMI-induced HF. Historically, lactate dehydrogenase, or LDH, was also used but is non-specific. Aim: In order to assist and support early diagnosis of acute myocardial infarction (AMI), suspension array technology was established for multiplexed, rapid and accurate measurement of AMI biomarkers in serum samples.Methodology & results: It was developed by coating AMI biomarkers on distinguishable microbeads and competing with free biomarkers for complementary antibodies. The first documented definition of acute MI was established in 1979 by the World Health Organization (WHO). Heart attack, MI & AMI are common terms you might have heard all being associated to the heart. Myocardial infarction is diagnosed when blood levels of sensitive and specific cardiac biomarkers such as cardiac troponin or CK-MB are elevated in the clinical setting of acute myocardial ischemia [33, 49, 50]. Troponin is a highly sensitive and specific biomarker for AMI diagnosis and can independently predict adverse cardiac events. Background: Mitochondrial biomarkers have been investigated in different critical settings, including ST-elevation myocardial infarction (STEMI). Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Cardiac biomarkers should be measured in all patients who present with chest discomfort consistent with acute coronary syndrome (ACS).Elevations of cardiac enzyme levels should be interpreted in the context of clinical and ECG findings [].. Cardiac troponins T and I are the preferred markers for myocardial injury as they have the highest sensitivities and specificities for the diagnosis … Dolci A, Panteghini M. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Ladenson JH. • ST-Segment Elevation Myocardial Infarction (STEMI): ACS symptoms with elevated cardiac biomarkers (troponin); ECG shows persistent ST elevation or new left bundle branch block (O’Gara et al, 2013). Authors Xi-Ying Wang 1 , Fen Zhang 1 , Chi Zhang 1 , Liang-Rong Zheng 1 , Jian Yang 1 Affiliation 1 Department of … The fast diagnosis of acute myocardial infarction (AMI) is a vital step. ABSTRACTBACKGROUND: Myocardial infarction (MI) as a term for a heart attack happens due to reduced blood flow to heart myocardium and lack of oxygen supply caused by plaques in the interior walls of coronary arteries.With respect to the importance of MI etiology, we aimed to study the relationship of MI and blood examination variables.METHODS: This study was conducted in … During the last several years there has been a burgeoning interest in circulating microRNAs as potential novel biomarkers for acute myocardial infarction. They can be useful in the early prediction or diagnosis of disease. Clin Chim Acta. Myocardial infarction results in cardiac injury and extensive tissue necrosis. Myocardial infarction (MI) is one of the leading causes of death worldwide, and knowing the early warning signs of MI is lifesaving. Here we aim to screen the differentially expressed genes (DEGs) as biomarkers for early diagnosis of AMI. doi: 10.1016/j.cca.2006.02.042. Patients can be stratified by symptoms, risk factors and electrocardiogram results but cardiac biomarkers also have a … Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Better diagnostic and prognostic biomarkers for clinical applications are the consistent pursuit of MI research. The gold standard for the diagnosis of AMI, the cardiac … Inflammation plays a central role in the etiology of myocardial infarction (MI) [6] and other clinical manifestation of coronary events (1). microRNAs (miRNAs) can be used as biomarkers for acute myocardial infarction (AMI). Use as Template. With effective treatment within our grasp, accurate and rapid diagnosis is of major medical and economic importance. Myocardial necrosis identified by a rise and/or fall of cardiac biomarkers to or from a level greater than the 99th percentile of the upper limit of reference range. Established biomarkers, basically hs-cTn and natriuretic peptides, as well as clinical scores such as the Global Registry of Acute Coronary Events (GRACE) or the Thrombolysis In Myocardial Infarction (TIMI) Risk Score enable excellent risk stratification, are widely available and cost effective . TROPONIN T AND H-FABP RAPID STRIP TEST FOR EARLIER DIAGNOSIS OF MYOCARDIAL INFARCTION Introduction Myocardial infarction (MI) is a subset of the spectrum of the disease known as acute coronary syndrome (ACS), which comprises three distinct entities including unstable angina (UA) and MI with or without ST-segment elevation. We examined original studies of patients, admitted with acute MI, reporting measurement of ≥ 1 circulating biomarker. Nanomedicine: Nanotechnology, Biology and … Biomarkers for Postoperative Myocardial Infarction in Cardiac Surgery. Cardiac MRI can assess the size of myocardial infarction and many other parameters associated with myocardial injury: edema, hemorrhage, micro-vascular obstruction. Circulating microRNAs (miRNAs) may act as diagnostic and prognostic biomarkers for cardiovascular events. Type 4b: Myocardial infarction related to stent thrombosis – Myocardial infarction associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/ or fall of cardiac biomarkers values with at least one value above the 99th percentile URL. The comparative utility of serum and saliva as diagnostic fluids for identifying biomarkers of acute myocardial infarction (AMI) was investigated. References •This lecture •Hand-outs. Acute coronary syndrome (ACS) can be divided into subgroups of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. The Biomarkers for Acute Myocardial Infarction and Heart Failure Biomed Res Int. 2 AMI is a condition that can be due to ischemic heart disease or coronary artery disease in conjunction, and it becomes manifest when an … These conditions can be satisfied by a rise of cardiac biomarkers (preferably cardiac troponin [cTn]) above the 99th percentile of the upper reference limit (URL) plus at least one of the following: also known as a "heart attack" Types ST-segment elevation myocardial infarction (STEMI) an acute coronary syndrome (ACS) with ST-segment elevations found on electrocardiogram (ECG) biomarkers of myocardial necrosis are present Cardiac markers are biomarkers measured to evaluate heart function. These patients should be considered for immediate reperfusion therapy (fibrinolysis or percutaneous coronary Animal models are widely used in the research of cardiovascular disease pathogenesis and drug therapy . Listing a study does not mean it has been evaluated by the U.S. Federal Government. Related Papers. Introduction. We identified the common DEGs in these two … Today, the diagnosis of an acute myocardial infarction depends on observation of a rise and/or fall of blood biomarkers, with at least one value above the 99 th percentile, in addition to clinical information or electrocardiographic changes. With effective treatment within our grasp, accurate and rapid diagnosis is of major medical and economic importance. By Andy Kristyagita and Bambang B Siswanto. The diagnosis of acute myocardial infarction (AMI) involves multiple clinical tools including physical assessment, ECG, and the evaluation of cardiac biomarkers. However, it remains to be determined how to diagnose, risk stratify and treat patients with T2MI. Keywords: Left ventricular remodeling; New biomarkers; Acute myocardial infarction Introduction Myocardial infarction (MI) occurs as a result of coronary artery In the broadest context, biological markers, or biomarkers, are molecules that characterize a biological system or process. 3. It included in the criteria for MI diagnosis the recommendation to use the Cardiovascular Biomarkers in Type 2 Myocardial Infarction May 5, 2021 Accurate and rapid noninvasive discrimination of type 2 myocardial infarction (T2MI), caused by the supply-demand mismatch from type-1 myocardial infarction (T1MI), is essential as the treatment for the condition differed significantly. The identification of new effective biological markers for AMI is a prerequisite for treatment. Cardiac biomarkers play critical roles in the diagnosis and prognosis of AMI. us, early recognition of AMI patients at risk of developing HF is an eective strategy for the reduction of HF incidence. Biomarkers of Acute Myocardial Infarction in the Elderly: Troponin and Beyond Notes/Citation Information Published inClinical Interventions in Aging, v. 9, p. 1081-1090. J Clin Exp Cardiolog 3:222. doi: 10.4172/2155-9880.1000222. 2006;369(2):179–187. Most of the early markers identified were enzymes, and as a result, the term "cardiac enzymes" is sometimes used. Biomarkers of myocardial infarction Dr. Mamoun Ahram Cardiovascular system, 2013. 1. With the advent of more sensitive cardiac troponin assays, biomarkers previously used to detect myocardial infarction, such as creatine kinase, creatine kinase MB isoform or myoglobin, became less relevant owing to their decreased sensitivity and specificity compared with hs-cTn [2, 10]. However, few reports have focused on the value of exosomal miRNAs in the mechanism of the pathophysiological process from stable coronary artery disease (SCAD) to AMI. Volume 3 • Issue 11 • 1000222. Myocardial infarction (MI) is the most common result of coronary heart disease (CHD), and often result from atherosclerotic plaque rupture. Results: We designed a case–control, two‑stage, epigenome‑wide association study on AMI (n discovery = 391, The overall prevalence of myocardial infarction (MI) in the US is around 3% in adults ages 20 years or over. 5. In addition, it remains the only biomarker whose release has been shown to depend on irreversible myocardial … ";s:7:"keyword";s:35:"biomarkers of myocardial infarction";s:5:"links";s:918:"Marco Island Seafood Festival 2021, Marc Anthony Zodiac Sign, Breonna Taylor Magazine Cover Vanity Fair, Lady Luck Winning Slots, Croscill Sapphire Bedding Collection, Chiropractor Abingdon, Va, Another Word For Healing Process, Ice Deportation List By Country, ";s:7:"expired";i:-1;}